Table 2.

Association of non-IBD comorbidities and adverse COVID-19 outcomes (hospitalization and death) in IBD patients with COVID-19 in the SECURE-IBD registry in separate models

Comorbidity	aOR (95% CI)a	P value
Asthmab	1.88 (1.21–2.92)	0.005
Cancerc	1.96 (1.01–3.81)	0.047
Cardiovascular diseased	1.86 (1.25–2.78)	0.002
Chronic liver diseasee	2.33 (1.39–3.89)	0.001
Chronic kidney diseasef	3.73 (1.84–7.56)	< 0.001
COPDg	3.55 (1.66–7.58)	0.001
Diabetesh	2.73 (1.79–4.18)	< 0.001
History of strokei	1.62 (0.71–3.70)	0.249
Hypertensionj	2.01 (1.48–2.73)	< 0.001
Obesityk	1.07 (0.80–1.43)	0.635
Other chronic lung diseasel	3.02 (1.39–6.55)	0.005

SECURE-IBD Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease, COVID-19 coronavirus disease 2019, COPD chronic obstructive pulmonary disease, aOR adjusted odds ratio, CI confidence interval

^aEach comorbidity was tested in a separate model after adjusting for variables other than comorbidities that were significantly associated with the outcome on bivariate analyses

^bAdjusted for age, sex, race, and ethnicity

^cAdjusted for age, sex, race, biologic therapy, 5-ASA, immunomodulators, and cigarette use

^dAdjusted for age, sex, biologic therapy, 5-ASA, corticosteroids, and cigarette use

^eAdjusted for age and sex

^fAdjusted for age, sex, race, biologic therapy, and corticosteroids

^gAdjusted for age, sex, biologic therapy, 5-ASA, and corticosteroids

^hAdjusted for age, sex, race, ethnicity, biologic therapy, and 5-ASA

ⁱAdjusted for age, sex, race, biologic therapy, and cigarette use

^jAdjusted for age, sex, race, biologic therapy, 5-ASA, and cigarette use

^kAdjusted for age, sex, biologic therapy, 5-ASA, and corticosteroids

^lAdjusted for age, sex, race, biologic therapy, 5-ASA, corticosteroids, and cigarette use